ObjectiveTo investigate the effect of different doses of Rosuvastatin on blood lipids in patients with coronary heart disease after interventional therapy.M ethodsAltogether 160 patientswith coronary heart disease who underwent interventional therapy and were treated in our hospital from February 2014 to April 2016 were selected and randomly divided into 4 groups,40 cases in each group.Control group receivedroutine treatment;while the other three groupswere treated with Rosuvastatin 5mg/d(group A),10mg/d(group B),20mg/d(group C)on the basisof routine treatment.The effects of different doses of Risuvastatin on blood lipid in patients and their safety of 4 groupswere observed.ResultsAfter treatment,the TC and LDL-C of group A,B,C were significantly improved compared with those before treatment,and better than those of control group,and the differences were statistically significant(P＜0.05);but the TG and HDL-C after treatment of each group had no significant difference in contrastwith those before treatment(P＞0.05).The tatal incidence of cardiac ischemic events in group A,B and C was significantly lower than that in the control group,and the differenceswere statistically significant(P＜0.05);the total incidence of other adverse reactions in group B and C was higher than that in the control group,and the differences were statistically significant(P＜0.05).ConclusionApplication of Rosuvastatin in coronary heart disease patients after interventional therapy can effectively improve the TC and LDL-C level and avoid ischemic events.With the increase of dose,the greater impact will be produced,but the risk of adverse reactionswill also increase.
杨发春. 不同剂量瑞舒伐他汀对冠心病介入治疗患者血脂的影响分析[J]. 中国当代医药, 2017, 24(22): 30-32.
YANG Fa-chun. Effect analysis of different doses of Rosuvastatin on blood lipids in patientsw ith coronary heart disease after interventional therapy. 中国当代医药, 2017, 24(22): 30-32.
Rizzo G，Raffeiner B，Coran A，et al.Pixel-based approach to assess contrast-enhanced ultrasound kinetics parameters for differential diagnosis of rheumatoid arthritis[J].JMed Imaging （Bellingham），2015，2（3）：34503.
[10]
Bartels LE，Jorgensen SP，Bendix M，et al.25-Hydroxy vitamin D3 modulates dendritic cell phenotype and function in Crohn′s disease[J].Inflammopharmacology，2013，21（2）：177-186.
[11]
Jagtap VR，Ganu JV，Nagane NS.BMD and serum intact osteocalcin in postmenopausal osteoporosis women[J].Indian JClin Biochem，2011，26（1）：70-73.
[12]
Sim MF，Stone M，Johansen A，et al.Cost effectiveness analysisof BMD referral for DXA usingultrasound asa selective pre-screen in a group of women with low trauma Colles′fractures[J].Technol Health Care，2014，8（5）：277-284.
[13]
Osorio J.Osteoporosis：Not all BMD is created equal[J].Nat Rev Rheumatol，2016，12（4）：192.
[14]
BahtiriE，IslamiH，RexhepiS，etal.Relationship ofhomocysteine levels with lumbar spine and femur neck BMD in postmenopausalwomen[J].Acta Reumatol Port，2015，40（4）：355-362.
[15]
Fotland T，Paulsen JE，Sanner T，et al.Risk assessment of coumarin using the benchmark dose （BMD） approach：children in Norway which regularly eat oatmeal porridge with cinnamon may exceed the TDI for coumarin with several folds[J].Food Chem Toxicol，2012，50（3-4）：903-912.
[16]
Effat LK，El-Harouni AA，Amr KS，et al.Screening of dystrophin gene deletions in Egyptian patients with DMD/BMDmuscular dystrophies[J].Dis Markers，2013，16（3-4）：125-129.
[17]
Roest PA，BoutM，Tuijn ACVD，et al.Splicingmutations in DMD/BMD detected by RT-PCR/PTT：detection of a 19AA insertion in the cysteine rich domain of dystrophin compatible with BMD[J].JMed Genet，2016，33（11）：935-939.
京公网安备 11010502046607号